A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB054707 When Administered Orally to Healthy Japanese Participants
Latest Information Update: 18 Sep 2022
At a glance
- Drugs Povorcitinib (Primary)
- Indications Hidradenitis suppurativa; Vitiligo
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Incyte Biosciences Japan
- 28 Apr 2022 Status changed from recruiting to completed.
- 12 Nov 2021 Status changed from not yet recruiting to recruiting.
- 08 Oct 2021 New trial record